Extended Data Fig. 5: LIMIT augments antigen-loaded MHC-I expression in vivo.
From: LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy
a, YUMM1.7-OVA cells carrying shFluc or shLimit were treated with IFNγ for 48 hours. Surface expression of OVA-H2Kb were determined by FACS. mean ± SD, n = 5 biological independent samples, P value by 2-sided t-test for end point tumor volume. b, Dot plot showing the CD45− gating of YUMM1.7-OVA tumor cells. c-d, Representative histogram showing the expression of H2Db (c) or OVA-H2Kb (d) in YUMM1.7-OVA shFluc or shLimit tumor cells. e-f, Statistical results of H2Db expression (e) or OVA-H2Kb expression (f) in YUMM1.7-OVA shFluc or shLimit tumor cells. mean ± SD, n = 5 biological independent samples, P value by 2-sided t-test. Source data are provided.
